These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34623544)

  • 21. Barth syndrome: cellular compensation of mitochondrial dysfunction and apoptosis inhibition due to changes in cardiolipin remodeling linked to tafazzin (TAZ) gene mutation.
    Gonzalvez F; D'Aurelio M; Boutant M; Moustapha A; Puech JP; Landes T; Arnauné-Pelloquin L; Vial G; Taleux N; Slomianny C; Wanders RJ; Houtkooper RH; Bellenguer P; Møller IM; Gottlieb E; Vaz FM; Manfredi G; Petit PX
    Biochim Biophys Acta; 2013 Aug; 1832(8):1194-206. PubMed ID: 23523468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of life in Barth syndrome.
    Kim AY; Vernon H; Manuel R; Almuqbil M; Hornby B
    Ther Adv Rare Dis; 2022; 3():26330040221093743. PubMed ID: 37180415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single Cell Transcriptomic Analysis in a Mouse Model of Barth Syndrome Reveals Cell-Specific Alterations in Gene Expression and Intercellular Communication.
    Perera G; Power L; Larson A; Codden CJ; Awata J; Batorsky R; Strathdee D; Chin MT
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tafazzin Mutation Affecting Cardiolipin Leads to Increased Mitochondrial Superoxide Anions and Mitophagy Inhibition in Barth Syndrome.
    Petit PX; Ardilla-Osorio H; Penalvia L; Rainey NE
    Cells; 2020 Oct; 9(10):. PubMed ID: 33096711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle.
    Ronvelia D; Greenwood J; Platt J; Hakim S; Zaragoza MV
    Mol Genet Metab; 2012 Nov; 107(3):428-32. PubMed ID: 23031367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late diagnosis of Barth syndrome in a 39-year-old patient with non-compaction cardiomyopathy and neutropenia.
    Seitz A; Hinck A; Bekeredjian R; Sechtem U
    ESC Heart Fail; 2020 Apr; 7(2):697-701. PubMed ID: 31967729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A simple mechanistic explanation for Barth syndrome and cardiolipin remodeling.
    Xu Y; Phoon CKL; Ren M; Schlame M
    J Inherit Metab Dis; 2022 Jan; 45(1):51-59. PubMed ID: 34611930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Function of Tafazzin, a Mitochondrial Phospholipid-Lysophospholipid Acyltransferase.
    Schlame M; Xu Y
    J Mol Biol; 2020 Aug; 432(18):5043-5051. PubMed ID: 32234310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mitochondrial respiratory chain supercomplexes are destabilized in Barth Syndrome patients.
    McKenzie M; Lazarou M; Thorburn DR; Ryan MT
    J Mol Biol; 2006 Aug; 361(3):462-9. PubMed ID: 16857210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of protein association causes cardiolipin degradation in Barth syndrome.
    Xu Y; Phoon CK; Berno B; D'Souza K; Hoedt E; Zhang G; Neubert TA; Epand RM; Ren M; Schlame M
    Nat Chem Biol; 2016 Aug; 12(8):641-7. PubMed ID: 27348092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
    Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
    FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac and clinical phenotype in Barth syndrome.
    Spencer CT; Bryant RM; Day J; Gonzalez IL; Colan SD; Thompson WR; Berthy J; Redfearn SP; Byrne BJ
    Pediatrics; 2006 Aug; 118(2):e337-46. PubMed ID: 16847078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Barth syndrome in a female patient.
    Cosson L; Toutain A; Simard G; Kulik W; Matyas G; Guichet A; Blasco H; Maakaroun-Vermesse Z; Vaillant MC; Le Caignec C; Chantepie A; Labarthe F
    Mol Genet Metab; 2012 May; 106(1):115-20. PubMed ID: 22410210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.
    Karaa A; Haas R; Goldstein A; Vockley J; Weaver WD; Cohen BH
    Neurology; 2018 Apr; 90(14):e1212-e1221. PubMed ID: 29500292
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted overexpression of catalase to mitochondria does not prevent cardioskeletal myopathy in Barth syndrome.
    Johnson JM; Ferrara PJ; Verkerke ARP; Coleman CB; Wentzler EJ; Neufer PD; Kew KA; de Castro Brás LE; Funai K
    J Mol Cell Cardiol; 2018 Aug; 121():94-102. PubMed ID: 30008435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of Mitochondrial Ca
    Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
    Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Barth Syndrome by Cardiolipin Manipulation (CARDIOMAN) With Bezafibrate: Protocol for a Randomized Placebo-Controlled Pilot Trial Conducted in the Nationally Commissioned Barth Syndrome Service.
    Dabner L; Pieles GE; Steward CG; Hamilton-Shield JP; Ness AR; Rogers CA; Bucciarelli-Ducci C; Greenwood R; Ellis L; Sheehan K; Reeves BC
    JMIR Res Protoc; 2021 May; 10(5):e22533. PubMed ID: 34057417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiolipin metabolism and Barth Syndrome.
    Hauff KD; Hatch GM
    Prog Lipid Res; 2006 Mar; 45(2):91-101. PubMed ID: 16442164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome.
    Dudek J; Cheng IF; Balleininger M; Vaz FM; Streckfuss-Bömeke K; Hübscher D; Vukotic M; Wanders RJ; Rehling P; Guan K
    Stem Cell Res; 2013 Sep; 11(2):806-19. PubMed ID: 23792436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promotion of plasmalogen biosynthesis reverse lipid changes in a Barth Syndrome cell model.
    Bozelli JC; Lu D; Atilla-Gokcumen GE; Epand RM
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158677. PubMed ID: 32126285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.